meta_analysis
    2024
    High Quality

    Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials

    Unknown authors

    Published in BMC Med

    Key Findings

    Microbiota-based therapies showed limited and heterogeneous benefit across autoimmune diseases, including type 1 diabetes.

    Conclusions

    Probiotics are not established disease-modifying therapy in autoimmune disease.

    Supplements Studied

    Probiotics
    Probiotic

    Gut microbiota-based therapies showed limited and heterogeneous benefit across autoimmune and rheumatic diseases.

    Related Health Concerns

    Type 1 Diabetes

    Study Details

    Year:2024
    Quality Score:8/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.